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Background: Pin2/TRF1 binding protein X1 (PinX1) has been identified as an endogenous telomerase inhibitor and
a major haploinsufficient tumor suppressor gene. Increasing evidence suggests that reduced expression of PinX1
plays a key role in tumorigenesis. However, the PinX1 expression status and its correlation with the
clinicopathological features in prostate cancer (PCa) have not been investigated.
Methods: PinX1 mRNA and protein expression in PCa and adjacent normal prostate tissues were evaluated by
real-time quantitative RT-PCR (qRT-PCR) and western blotting. The clinicopathological significance of PinX1 was
investigated by immunohistochemistry (IHC) analysis on a PCa tissue microarray (TMA). The cut-off score for positive
expression of PinX1 was determined by the receiver operating characteristic (ROC) analysis. The correlation between
PinX1 expression and clinicopathological features of PCa was analyzed by Chi-square test.
Results: Reduced expression of PinX1 mRNA and protein was observed in the majority of PCa, compared with their
paired adjacent normal prostate tissues. When PinX1 positive expression percentage was determined to be above
60% (area under ROC curve = 0.833, P = 0.000), positive expression of PinX1 was observed in 100% (8/8) of normal
prostate tissues and 32.5% (13/40) of PCa tissues by IHC. Reduced expression of PinX1 in patients was correlated
with advanced clinical stage (χ2 = 10.230, p = 0.017), high Gleason score (χ2 = 4.019, p = 0.045), positive regional
lymph node metastasis (χ2 = 10.852, p = 0.004) and distant metastasis (χ2 = 7.965, p = 0.005).
Conclusions: Our findings suggest that reduced expression of PinX1 is correlates to progressive features in patients
with PCa and may serve as a potential marker for diagnosis.
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Prostate cancer (PCa) is the second most frequently diag-
nosed cancer and the sixth leading cause of cancer death
in males worldwide [1,2]. The most common histological
subtype of PCa is adenocarcinoma, which derives from
the semen-secreting prostate gland cells. Although most
PCa present as noninvasive adenocarcinoma, there are
cases of aggressive PCa which could metastasize primarily
to the bones [3,4], and also lymph nodes, rectum, bladder,
lower ureters, etc. To date, the most important clinical* Correspondence: jueyuzhou80@126.com; tanwanlongnfyy@126.com
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unless otherwise stated.prognostic indicators of PCa are pTNM stage, Gleason
score and pre-therapy PSA level. However, the mechanism
contributes to the progression of PCa remains unclear and
many variations among individual patients are unex-
plained. Thus, novel biomarkers are strongly needed to
enable more accurate diagnosis, prognosis and individual-
ized medication of PCa [5].
Pin2/TRF1 binding protein X1 (PinX1) has been identi-
fied as an endogenous telomerase inhibitor and a major
haploinsufficient tumor suppressor gene localized at hu-
man chromosome 8p23, a region with frequent loss of het-
erozygosity in a number of human cancers [6]. Increasing
evidence suggest that reduced expression of PinX1 plays a
key role in tumorigenesis. Zhou et al. reported that PinX1
expression was reduced in most human breast cancer. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Shi et al. Cancer Cell International 2014, 14:46 Page 2 of 7
http://www.cancerci.com/content/14/1/46tissues and cell lines, PinX1 allele loss caused majority of
mice to develop a variety of epithelial cancers, the mechan-
ism involves chromosome instability which recapitulated
to 8p23 allele loss in humans [7,8]. Cai et al. suggested that
decreased expression of PinX1 was correlated with poor
prognostic factors of ovarian carcinoma and loss of PinX1
was an adverse independent molecular marker for epithe-
lial ovarian carcinoma patients [9]. Kondo et al. reported
that LOH of PinX1 locus and hypoacetylation of histone
H4 in the 5' UTR of PinX1 were associated with reduced
expression of PinX1 in gastric carcinoma [10]. Ma et al. re-
ported that LOH of PinX1 was associated with the TNM
stage of the gastric carcinoma specimens, and could be
regarded as a sign of gastric cancer development [11]. Park
et al. suggested that LOH of PinX1 might occur as an early
event in the development of hepatocellular carcinoma, es-
pecially in the cases with HBV infection [12]. Moreover,
the role of PinX1 as a putative tumor suppressor was
proved by several other groups in different cancer cell lines
[13-18]. However, the PinX1 expression status and its cor-
relation with the clinicopathological features in PCa have
not been investigated.
In this study, PinX1 mRNA and protein expression in
PCa and adjacent normal prostate tissues were evaluated
by real-time quantitative RT-PCR (qRT-PCR) and western
blotting. Immunohistochemistry (IHC) analysis for PinX1
was performed on a PCa tissue microarray (TMA). Here
we report the expression of PinX1 mRNA and protein was
decreased in PCa. Reduced expression of PinX1 was corre-
lated to progressive features in patients with PCa.
Results
Expression of PinX1 mRNA and protein in paired PCa and
adjacent normal prostate tissues
The qRT-PCR result showed that in 14 of the 16 sample
pairs, fold changes (the 2-△△Ct values) were less than 1 be-
tween PCa and adjacent normal prostate tissue (Figure 1A),
which indicated the PinX1 mRNA expression was down-
regulated in PCa tissues compared to the adjacent normal
prostate tissues. The mean fold change is 0.385 and paired
t-test showed that difference between the two groups
was statistically significant (P < 0.0001, Figure 1B). Western
blotting analysis also demonstrated down-regulation of the
PinX1 protein in 15 of the 16 PCa tissues compared to their
adjacent normal counterparts (Figure 1C). The mean op-
tical density value of the PCa tissues is 0.306 fold of the ad-
jacent normal tissues. The difference of the PinX1 protein
expression between the two groups was also statistically sig-
nificant by paired t-test (P < 0.0001, Figure 1D).
Expression of PinX1 in PCa by IHC and cut-off
score selection
The subcellular localization and expression of the PinX1
protein were observed and scored by IHC on the TMA,which including 40 prostate adenocarcinoma and 8 normal
prostate tissues. IHC result showed that the PinX1 protein
was primarily stained in cell nucleus, while in the cyto-
plasm, a lesser staining could also be observed (Figure 2).
The receiver operating characteristic (ROC) curve for all
the clinicopathological features at different PinX1 scope
were plotted (Figure 3), the corresponding area under the
ROC curve (AUC) and P-value were analyzed by the SPSS
13.0 software (Table 1). Optimal cut-off score for PinX1
was determined by the ROC curve for pM which showed
the shortest distance to the point (0.0,1.0) and could
maximize both the sensitivity and specificity. Based on the
cut-off score, tissues were defined as PinX1 positive when
PinX1 expression percentage was above 60%. According to
the PinX1 scores for each sample and the cut-off score de-
termined by the ROC curve analysis, positive expression of
PinX1 was detected in 32.5% (13/40) of PCa and 100% (8/
8) of the normal prostate tissues.
Relationship between PinX1 expression and
clinicopathological characteristics of PCa patients
The relationship between PinX1 scores with respect to
patient clinicopathological features was listed in Table 2.
The result indicated that reduced expression of PinX1
in patients was correlated with advanced clinical stage
(χ2 = 10.230, p = 0.017), high Gleason score (χ2 = 4.019,
p = 0.045), positive regional lymph node metastasis (χ2 =
10.852, p = 0.004) and distant metastasis (χ2 = 7.965, p =
0.005). There was no statistically significant correlations
between PinX1 expression and other features, such as age,
histology grade, Gleason pattern or pT status (P > 0.05).
Discussion
At prescent, PSA is still the most commonly used molecu-
lar markers for the diagnosis of PCa. However, due to the
drawback of PSA as a nonspecific biomarker, nontumor
patients who underwent diagnostic prostate biopsies and
clinically insignificant PCa patients who received over-
treatments had increased globally. This had not only
placed great physical and psychological burden on the pa-
tients, but also increased the cost on health care of the
governments. Therefore, novel biomarkers such as PCA3,
TMPRSS2-ERG and some microRNAs [19] etc. have been
assessed for their diagnostic and prognostic role in PCa,
especially the detection of these biomarker in the body
fluid such as blood, urine or seminal fluid.
Tissue biomarkers such as Ki-67, PTEN, E-Cadherin,
EZH2, SPINK and ERG are important for evaluating the
prognosis of the patients after the prostate biopsies or rad-
ical prostatectomy. Khatami et al. [20]. proved the correl-
ation of Ki-67 to prostate-specific antigen doubling time
(PSADT), Gleason score, and its role as a valuable prog-
nostic marker of PSA relapse after radical prostatectomy in
men with screen-detected, low-grade, low-stage PCa. Ritu
Figure 1 qRT-PCR and Western blot analysis of PinX1 expression in paired PCa and adjacent normal prostate tissues. (A) Fold changes
(2-△△Ct values) by qRT-PCR showed a reduced expression of PinX1 mRNA in the majority of PCa cases (14/16),when compared with paired normal
prostate tissues. Expression levels were normalized for GAPDH. (B) Significant differences of PinX1 mRNA expression between the PCa and adjacent
normal prostate tissues (P < 0.0001). (C) Western blotting indicated down-regulation of PinX1 protein in PCa tissues (15/16) in comparison with the
adjacent normal prostate tissues. β-actin was used as internal control. T, PCa; N, normal. (D) Significant differences of PinX1 protein expression between
the PCa and adjacent normal prostate tissues (P < 0.0001).
Figure 2 The expression of PinX1 protein in normal prostate and PCa tissues by IHC on the TMA. (A) Positive expression of PinX1 in
normal prostate tissue, in which about 100% of the prostate epithelial cells demonstrated a strong nuclear staining of PinX1, while a lesser
staining in the cytoplasm could also be observed (100x). (B) Positive expression of PinX1 in PCa (case 21), in which more than 90% of tumor cells
showed positive staining (100x). (C) Negative expression of PinX1 in PCa (case 11), with less than 40% positive tumor cells (100x). (D) Negative
expression of PinX1 in PCa (case 27), with less than 35% positive tumor cells (100x). (E) Negative expression of PinX1 in PCa (case 25), with less
than 15% positive tumor cells (100x). (F), (G), (H), (I) and (J) demonstrate the higher magnification (400x) from the area of black square in
(A), (B), (C), (D) and (E), respectively.
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Figure 3 Selection of the optimum cut-off score for positive expression of PinX1 by receiver operating characteristic (ROC) analysis.
Various ROC curves were plotted by sensitivity and specificity for each outcome: age (A), histological grade (B), clinical stage (C), Gleason pattern
(D), Gleason grade (E), pT status (F), pN status (G), pM status (H).
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ical method recently which could simultaneously detect the
ERG-PTEN and ERG-SPINK1 status in PCa. In addition,
novel gene panel which detect and score the expression of
31 genes simultaneously was also developed for evaluating
the prognosis of PCa [22,23]. Although the progress ap-
pears to be encouraging, there is still an urgent need for
new objective strategies and novel biomarkers for diagnosis,
prognosis and evaluation of drug resistance.
PinX1 is a newly identified telomere-associated pro-
tein which was recruited to the telomeres by TRF1, pro-
vided a critical link between TRF1 and telomerase
inhibition to help maintain telomere homeostasis [24].Table 1 Area under the ROC curve for each
clinicopathological features
Characteristics AUC (95% CI) P-value
Age 0.508 (0.352-0.690) 0.935
Grade 0.668 (0.485-0.850) 0.084
Stage 0.805 (0.670-0.940) 0.002
Gleason pattern 0.671 (0.503-0.840) 0.064
Gleason score 0.668 (0.491-0.845) 0.078
pT 0.675 (0.503-0.848) 0.061
pN 0.808 (0.673-0.942) 0.001
pM 0.833 (0.709-0.957) 0.000
ROC, the receiver–operator curve; AUC, area under the curve.Reduced expression of PinX1 has been implicated in
various human cancers, such as breast cancer [7], ovar-
ian cancer [9], gastric cancer [10,11] and liver cancer
[12], which suggested a tumor suppressor role of pinX1 in
multiple human cancers. However, the relationship be-
tween PinX1 expression status and clinicopathological fea-
tures of PCa has not been reported so far. In this study,
qRT-PCR and western blotting were applied to examine
the expression levels of both the PinX1 mRNA and pro-
tein in paired PCa and adjacent normal prostate tissue
samples. The results were in line with expectations that
reduced expression of PinX1 mRNA and protein were ob-
served in the majority of PCa, when compared with their
paired adjacent normal prostate tissues (P < 0.05).
In addition, the expression of PinX1 protein was ex-
amined by IHC on a TMA including 40 adenocarcinoma
and 8 normal prostate tissues. Our results demonstrated
that reduced expression of PinX1 was frequently ob-
served in PCa tissues, whereas all the normal prostate tis-
sues showed a deep staining of PinX1. This was in accord
with the qRT-PCR and western blotting results. Further
correlation analysis revealed that reduced expression of
PinX1 was correlated to higher Gleason score and poor
prognosis regarding presence of advanced clinical stage,
higher N status and higher M status. These findings sug-
gest that, as a major haploinsufficient tumor suppressor
gene, PinX1 expression was correlated to the risk of PCa
progression and may serve as a potential marker for the
Table 2 Association of PinX1 expression with clinicopathological characteristics of PCa patients
Characteristics PinX1 staining Total Pearson
Chi-square
P valueb
Negative (%) Positive (%)
Age at surgery (years)
≤67a 13 (72.2) 5 (27.8) 18 0.333 0.564
>67 14 (63.6) 8 (36.4) 22
Histology grade
I 4 (50.0) 4 (50.0) 8 3.569 0.168
II 11 (61.1) 7 (38.9) 18
III 12 (85.7) 2 (14.3) 14
Clinical stage
I 0 (0.0) 1 (100.0) 1 10.230 0.017
II 6 (46.2) 7 (53.8) 13
III 3 (50.0) 3 (50.0) 6
IV 18 (90.0) 2 (10.0) 20
Gleason pattern
1 1 (33.3) 2 (66.7) 3 4.177 0.383
2 6 (66.7) 3 (33.3) 9
3 4 (50.0) 4 (50.0) 8
4 9 (81.8) 2 (18.2) 11
5 7 (77.8) 2 (22.2) 9
Gleason score
1-7 14 (56.0) 11 (44.0) 25 4.019 0.045
8-10 13 (86.7) 2 (13.3) 15
pT status
T1 0 (0.0) 1 (100.0) 1 7.322 0.062
T2 9 (52.9) 8 (47.1) 17
T3 11 (73.3) 4 (26.7) 15
T4 7 (100.0) 0 (0.0) 7
pN status
N0 9 (45.0) 11 (55.0) 20 10.852 0.004
N1 17 (94.4) 1 (5.6) 18
N2 1 (50.0) 1 (50.0) 2
pM status
M0 10 (47.6) 11 (52.4) 21 7.965 0.005
M1 17 (89.5) 2 (10.5) 19
aMedian age.
bP value are from Chi-square test.
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mechanisms of PinX1 in PCa carcinogenesis and validation
in large clinical trials are necessary for subsequently imple-
ment of PinX1 as a biomarker in the clinical practice.
Conclusions
Our findings suggest that PinX1 was down-regulated
in PCa compared to adjacent normal prostate tissues.
Reduced expression of PinX1 is significantly correlated
with low differentiation and adverse clinical features inPCa. PinX1 may serve as a potential marker for the
diagnosis of PCa.
Methods
Patients and primary PCa samples
In this study, 16 fresh paired prostate adenocarcinoma
and adjacent normal prostate tissue samples were col-
lected from patients for qRT-PCR and western blotting
analysis between September 2011 and June 2013. A total
of 48 paraffin-embedded tissues diagnosed between 2003
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analysis. All the samples were collected from the De-
partment of Urinary Surgery, Nanfang Hospital of
Southern Medical University (Guangzhou, China). The
samples selected were pathologically diagnosed cases
of PCa, having received no prior chemotherapy or
radiotherapy before surgery. Ages of the 40 patients
with PCa ranged from 22 to 78 years (median, 67 years),
clinicopathological features of patients including age at
diagnosis, histological grade, Gleason pattern, Gleason
score, clinical stage and pTNM status were listed in
Additional file 1: Table S1. Written informed consent
was obtained from all patients for use of the tissue
samples and clinical records. The study protocol was
performed under the approval by the Ethic Committee
of the Nanfang Hospital.
RNA isolation and qRT-PCR analysis
Total RNAs were isolated from 16 pairs of fresh PCa and
adjacent normal prostate tissues using RNAiso Plus re-
agent (Takara, Dalian, China). RNA concentration and
OD260/280 were assessed by using a Biophotometer plus
spectrophotometer (Eppendorf, Germany). The integrity
of total RNAs were confirmed by denaturing agarose gel
electrophoresis. Qualified total RNAs were reversely tran-
scribed into first-strand cDNAs by using the PrimeScript®
RT reagent Kit (Takara, Dalian, China). The 50 μL PCR re-
action included 80 ng of the cDNA template, 0.4 μM of
the forward and reverse primers each, 25 μL of the 2×
SYBR Premix Ex Taq™ II (Takara, Dalian, China), and
ddH2O. For the PinX1 gene, the forward primer was 5’- C
CAGAGGAGAACGAAACCACG -3’, and the reverse pri-
mer was 5’- ACCTGCGTCTCA GAAATGTCA -3’. For the
GAPDH gene, the forward primer was 5’- CTGGGCTAC
ACTGAGCACC -3’, and the reverse primer was 5’- AAG
TGGTCGTTGAGGGCAATG -3’. The PCR was performed
in an ABI 7500 real-time PCR amplifier (ABI, USA) with an
initial denaturing temperature of 95°C for 30 s, followed by
40 cycles of 95°C for 5 s, 60°C for 34 s. The Ct values were
acquired using the 7500 system SDS software (ABI, USA)
with manual thresholds. Expression of PinX1 was normal-
ized by using GADPH as an internal control. The fold
changes between PCa and normal tissue pairs were analyzed
by calculating the 2-△△Ct values. Each PCR reaction was re-
peated in triplicate for stable results.
Western blotting analysis
Total proteins from 16 pairs of fresh PCa and adjacent nor-
mal tissues were extracted using radio-immunoprecipitation
assay (RIPA) buffer containing 1 mM PMSF (Beyotime,
Haimen, China). Then protein concentration was deter-
mined by the TECAN Infinite 200 microplate reader
(TECAN, Austria) at 562 nm using BCA Protein Assay
Kit (Beyotime, Haimen, China). 50 μg of each proteinsample was loaded on the 10% SDS polyacrylamide gels
for electrophoresis. Proteins separated on the gel were
then transferred to polyvinylidene fluoride (PVDF) mem-
brane (Millipore, USA) by a Transblot SD Cell semi-dry
transfer machine (BioRad, USA). The membranes were
blocked by 5% nonfat milk. Goat polyclonal anti-PinX1
antibody (1:500, Santa Cruz Biotechnology, Santa Cruz,
USA) and HRP conjugated rabbit anti-goat IgG (1:5000,
Multisciences, Hangzhou, China) were used to detect the
PinX1 protein. Mouse monoclonal anti-β-actin antibody
(1:2000, Multisciences, Hangzhou, China) and HRP conju-
gated goat anti-mouse IgG antibody (1:5000, Multi-
sciences, Hangzhou, China) were used to detect β-actin.
BeyoECL Plus Kit (Beyotime, Haimen, China) was used
for the detection of HRP on the antigen-antibody com-
plex. Finally, the result of western blotting was visualized
by the Image Station 4000R PRO scanner (CareStream
Health, U.S.A.).
TMA construction and IHC
Representative sections of PCa or normal prostate in the
pre-existing paraffin-embedded tissue blocks were deter-
mined according to the overlaid H&E staining slides. The
TMA was done by using a needle to punch a 1.8 mm
diameter cylinder in the representative section of each
block, and placing the cylinders into an array on a recipi-
ent paraffin block. 5 μm thick multiple sections were cut
from the TMA block and mounted on microscope slides
for immuohistochemistry analysis. The TMA slides were
dried overnight at 37°C, deparaffinized in xylene and then
rehydrated in graded ethanol. The endogenous hydrogen
peroxidase activities of the TMA were inhibited by im-
mersing the slide into 3% H2O2. Antigen retrieval was
done by microwave heating with sodium citrate buffer
(pH 6.0) at 100°C for 20 min. The TMA slides were
blocked with 5% normal goat serum at room temperature
for 30 min, followed by incubation with polyclonal anti-
PinX1 antibody (1:200, Santa Cruz Biotechnology, Santa
Cruz, USA) at 4°C overnight, and polymer peroxidase-
labeled secondary antibody (ZSGB-Bio, Beijing, China) at
room temperature for 1 h. The TMA slides were stained by
using the DAB Horseradish Peroxidase Color Development
Kit (Beyotime, Haimen, China), and then counterstained by
hematoxylin. Phosphate buffered saline replaced anti-PinX1
primary antibody was used as a negative control, and
known IHC positive slide was used as a positive control.
IHC evaluation
Two investigators graded the immunohistochemical ex-
pression of PinX1 independently using a semi-quantitative
scoring method according to distribution, intensity, and
percentage of positive cells. With regard to distribution of
PinX1 protein, the scores were expressed as percentage of
positive tumor cells over the total tumor cells, by using 5%
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if both of the two investigators agree with the values.
Otherwise, the values were re-estimated until a consensus
was reached.
Selection of cut-off score and statistical analysis
Receiver operating characteristic (ROC) curve analysis
was applied for acquiring an optimal cut-off score for posi-
tive expression of PinX1 using the 0,1-criterion. The ROC
curves were generated by plotting the sensitivity and spe-
cificity for each outcome at different PinX1 scores. The
score which was closest to the point [0.0, 1.0] on the curve
with both maximum sensitivity and specificity was se-
lected as the cut-off value. Dichotomization of the clinico-
pathological features for ROC analysis were as follow: age
(≤67 vs. >67),histology grade (I-II vs. III), Gleason pattern
( 1–3 vs. 4–5 ), Gleason pattern (2–7 vs. 8–10), clinical
stage(I-II vs.III-IV), pT stage(T1-T2 vs.T3-T4), pN stage
(N0 vs. N1-N2) and pM stage(M0 vs. M1). Statistical
analyses were performed by SPSS 13.0 software (SPSS,
Chicago, IL, USA). The association of PinX1 expression
with clinicopathological features of PCa patients was ana-
lyzed by the Chi-square test. Differences were considered
significant when the P-value was <0.05 (two-tailed test ).
Additional file
Additional file 1: Table S1. Baseline demographic characteristics of the
patients with PCa for constructing the TMA and the IHC results of PinX1.
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